


Integrated chemistry services in ADC, oligo and peptide conjugate development and manufacturing

Our award-winning capabilities in ADC chemistry combine discovery expertise, high-potency handling, and manufacturing strength to drive consistent and rapid clinical and commercial development.



- Discovery and IND-enabling chemistry; cGMP chemistry and bioconjugation
- Global leading commercial supplier of S-Trione and SN-38
- High-potency handling: OEL < 10 ng/m³
- Custom payloads and linkers
- Supporting analytical services: biophysical analysis, method development, stability studies, and reference standards



ADC Services – Discovery to Commercial



Discovery & Early Development

- | | |
|---|---|
| • R&D antibody production (transient cell line) | ● |
| • Plate-based ADC screening | ● |
| • Linker-payload library | ● |
| • Technology evaluation / DAR optimization | ● |
| • Cell-based assays and biophysical analysis | ● |
| • Proof-of-concept hit discovery | ● |
| • In vivo studies | ● |



GMP Manufacturing

- | | |
|---|---|
| • Antibody (cGMP) | ○ |
| • Payload-linker (Phases I & II) | ● |
| • Payload-linker (Phases III & commercial) | ● |
| • cGMP ADC manufacturing (Phases I & II) | ● |
| • Fill-finish | ○ |
| • cGMP analytical services: method development, qualification, validation | ● |



Preclinical Development & Toxicology Batches

- | | |
|---|---|
| • Technology optimization | ● |
| • Payload-linker synthesis / custom solutions | ● |
| • ADC therapeutic index optimization | ● |
| • Bioanalytical support (in vivo / in vitro assays: ELISA, cytotoxicity, PK, serum stability) | ● |
| • Full analytical development | ● |
| • Tox batches (payload, linker, bioconjugate) | ● |
| • Process development optimization (scale-up) | ● |
| • Toxicology studies in non-human primates | ○ |



Back-integrated Linker Payloads

- | | |
|---|---|
| • S-Trione (US DMF No. 039042) | ● |
| • MMAE (DMF planned - Aug 2026) | ● |
| • Exatecan Mesylate (US DMF No. 043412) | ● |
| • SN-38 (US DMF No. 039031) | ● |
| • Camptothecin (DMF planned - Apr 2026) | ● |
| • Novel Topoisomerase I and Auristatins | ● |
| • Linkers: Standard & Novel | ● |



● NJ Bio, Princeton, NJ (USA) ● Nacharam (India) ○ Collaborators

